{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:37:15Z","timestamp":1790962635733,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["2023-508502-18-00"],"award-info":[{"award-number":["2023-508502-18-00"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["NCT05944016"],"award-info":[{"award-number":["NCT05944016"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["2023-508502-18-00"],"award-info":[{"award-number":["2023-508502-18-00"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["508779211"],"award-info":[{"award-number":["508779211"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs). Whether benefits extend to children, teenagers and young adults with early-stage CKD is unknown. For this reason, the DOUBLE PRO-TECT Alport trial (NCT05944016) will study the progression of albuminuria in young patients with Alport syndrome (AS), the most common hereditary CKD, to assess the safety and efficacy of the SGLT2 inhibitor dapagliflozin. Patients living with AS and chronically elevated albuminuria have a high risk of kidney failure before the age of 50\u00a0years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>DOUBLE PRO-TECT Alport is a multicentre, randomized, double-blind, placebo-controlled trial. Participants (ages 10\u201339\u00a0years) must have a diagnosis of AS by genetic testing or kidney biopsy, be on a stable (&amp;gt;3\u00a0months) maximum tolerated dose of a renin\u2013angiotensin system inhibitor and have a urinary albumin:creatinine ratio (UACR) of &amp;gt;300\u00a0mg\/g (paediatric) or &amp;gt;500\u00a0mg\/g (adult).<\/jats:p>\n                  <jats:p>Eligible participants will be randomly assigned at a 2:1 ratio to 48\u00a0weeks of treatment with dapaglifozin 10\u00a0mg\/day or matched placebo. Most participants are expected to be children with a normal estimated glomerular filtration rate (eGFR). In addition to safety, the primary (change in UACR from baseline to week 48) and key secondary (eGFR change from baseline to week 52) efficacy outcomes will be analysed with a mixed model repeated measures approach. Efficacy analyses will be performed primarily in the full analysis set according to the intention-to-treat principle. A sensitivity analysis will be performed using reference-based multiple imputation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DOUBLE PRO-TECT Alport will assess whether SGLT2 inhibitors can safely reduce the UACR change from baseline as a marker for progression of CKD in young patients living with AS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae180","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T02:11:39Z","timestamp":1723255899000},"page":"679-687","source":"Crossref","is-referenced-by-count":33,"title":["Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8852","authenticated-orcid":false,"given":"Oliver","family":"Gross","sequence":"first","affiliation":[{"name":"Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Boeckhaus","sequence":"additional","affiliation":[{"name":"Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T","family":"Weber","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, Children's and Adolescents\u2019 Hospital, University Hospital of Cologne, Faculty of Medicine, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Kidney Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rees","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Legal Department, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gerst","sequence":"additional","affiliation":[{"name":"Legal Department, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Duerr","sequence":"additional","affiliation":[{"name":"Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Clinical Trials Unit, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Walker","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Tostmann","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Helm","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7441","authenticated-orcid":false,"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen , G ttingen ,","place":["Germany"]},{"name":"\u00f6 , G ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the study group of the German Society of Pediatric Nephrology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Boeckhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rees","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Tostmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Helm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2025040116483495800_bib1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of CKD in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Percovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib4","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume-title":"N Engl J Med","author":"Heerspink","year":"2020"},{"key":"2025040116483495800_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib6","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"2025040116483495800_bib7","doi-asserted-by":"publisher","first-page":"e83353","DOI":"10.7554\/eLife.83353","article-title":"Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome","volume":"12","author":"Ge","year":"2023","journal-title":"eLife"},{"key":"2025040116483495800_bib8","first-page":"182","article-title":"Activation of renin in the single juxtaglomerular apparatus by sodium chloride in the tubular fluid at the macula densa","volume":"31","author":"Thurau","year":"1972","journal-title":"Circ Res"},{"key":"2025040116483495800_bib9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1152\/physrev.00042.2012","article-title":"Renal autoregulation in health and disease","volume":"95","author":"Carlstr\u00f6m","year":"2015","journal-title":"Physiol Rev"},{"key":"2025040116483495800_bib10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/CS20191276","article-title":"SGLT2 inhibitors\u2014a potential treatment for Alport syndrome","volume":"134","author":"Mabillard","year":"2020","journal-title":"Clin Sci"},{"key":"2025040116483495800_bib11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4158\/EP.14.6.782","article-title":"Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus","volume":"14","author":"Abdul-Ghani","year":"2008","journal-title":"Endocr Pract"},{"key":"2025040116483495800_bib12","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"2025040116483495800_bib13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2009070759","article-title":"Macula densa sensing and signaling mechanisms of renin release","volume":"21","author":"Peti-Peterdi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025040116483495800_bib14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"2025040116483495800_bib15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2025040116483495800_bib16","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport's syndrome, Goodpasture and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/cells12091333","article-title":"Ratio of urinary proteins to albumin excretion shifts substantially during progression of the podocytopathy Alport syndrome and spot-urine is a reliable method to detect these pathologic changes","volume":"12","author":"Boeckhaus","year":"2023","journal-title":"Cells"},{"key":"2025040116483495800_bib18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for CKD","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"key":"2025040116483495800_bib19","doi-asserted-by":"publisher","first-page":"18084","DOI":"10.1038\/s41598-023-45102-6","article-title":"GWAS for the composite traits of hematuria and albuminuria","volume-title":"Sci Rep","author":"Gagliano Taliun","year":"2023"},{"key":"2025040116483495800_bib20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib22","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00467-021-05040-9","article-title":"Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome","volume":"36","author":"Zhang","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2025040116483495800_bib23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib24","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/ndt\/gfad105","article-title":"Effectiveness of renin\u2013angiotensin\u2013aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis","volume":"38","author":"Zeng","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025040116483495800_bib25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Treatment recommendations clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2025040116483495800_bib26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","article-title":"Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy","volume":"24","author":"Savige","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025040116483495800_bib27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.kint.2020.01.030","article-title":"ACEi in Alport syndrome: are the benefits worth the risks?","volume":"97","author":"Rheault","year":"2020","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.kint.2020.02.029","article-title":"Clinical trial recommendations for potential Alport syndrome therapies","volume":"97","author":"Weinstock","year":"2020","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial indicates safety and efficacy of nephroprotective therapy in children with Alport's","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025040116483495800_bib31","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20233411B4c","article-title":"SGLT2 inhibition in Alport syndrome: first large-scale trial to plan a randomized controlled trial in children","volume-title":"TH-PO1117, Late-Breaking Clinical Trials Poster, Annual Meeting of the American Society of Nephrology","author":"Gross","year":"2023"},{"key":"2025040116483495800_bib32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome\u2014insights from basic and clinical research","volume":"9","author":"Kr\u00fcgel","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2025040116483495800_bib33","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cells10071815","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, Alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus","year":"2021","journal-title":"Cells"},{"key":"2025040116483495800_bib34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib35","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med;"},{"key":"2025040116483495800_bib36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ekir.2024.02.1404","article-title":"Fournier's gangrene in a CKD patient without diabetes possibly related to sodium glucose co-transporter 2 inhibitor therapy","volume":"9","author":"Heidegger","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025040116483495800_bib37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040116483495800_bib38","doi-asserted-by":"publisher","first-page":"e007165","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with trial sequential analysis","volume":"20","author":"Zhang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025040116483495800_bib39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"2025040116483495800_bib40","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone added to RAS\/SGLT2 blockade for chronic kidney disease in Alport syndrome. Results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice","volume":"34","author":"Zhu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025040116483495800_bib41","author":"European Medicines Agency"},{"key":"2025040116483495800_bib42","author":"European Medicines Agency"},{"key":"2025040116483495800_bib43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2215\/CJN.0000000000000167","article-title":"Overcoming barriers to drug development in children with CKD","volume":"18","author":"Khurana","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040116483495800_bib44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/ndt\/gfae029","article-title":"SGLT2 inhibitors: approved for adults and cats but not for children with CKD","volume":"39","author":"Gross","year":"2024","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae180\/58938661\/gfae180.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/4\/679\/58938661\/gfae180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/4\/679\/58938661\/gfae180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T18:17:48Z","timestamp":1743531468000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/4\/679\/7731148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,9]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae180","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,8,9]]}}}